The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Engineering cytokine therapeutics
Open accessAbstract
Cytokines have pivotal roles in immunity, making them attractive as therapeutics for a variety of immune-related disorders. However, the widespread clinical use of cytokines has been limited by their short blood half-lives and severe side effects caused by low specificity and unfavourable biodistribution. Innovations in bioengineering have aided in advancing our knowledge of cytokine biology and yielded new technologies for cytokine engineering. In this Review, we discuss how the development of bioanalytical methods, such as sequencing and high-resolution imaging combined with genetic techniques, have facilitated a better understanding of cytokine biology. We then present an overview of therapeutics arising from cytokine re-engineering, targeting and delivery, mRNA therapeutics and cell therapy. We also highlight the application of these strategies to adjust the immunological imbalance in different immune-mediated disorders, including cancer, infection and autoimmune diseases. Finally, we look ahead to the hurdles that must be overcome before cytokine therapeutics can live up to their full potential. Cytokines are key regulators of the immune system and can be recombinantly designed as therapeutics for immune-related disorders. However, the severe toxicity of recombinant cytokines limits their clinical translation. In this Review, the authors highlight bioengineering approaches for the design of clinically applicable and safe cytokine-based therapeutics. Cytokines are crucial regulators of the immune system and have important roles in health and disease. Recombinant cytokine therapy is hampered by the short blood half-life and severe side effects of cytokines. Increased knowledge of cytokine biology converges with new bioengineering approaches to develop engineered cytokine therapeutics. Cytokine therapeutics can be applied to modulate dysregulated immune responses in disorders such as cancer or autoimmune diseases. Cytokines are crucial regulators of the immune system and have important roles in health and disease. Recombinant cytokine therapy is hampered by the short blood half-life and severe side effects of cytokines. Increased knowledge of cytokine biology converges with new bioengineering approaches to develop engineered cytokine therapeutics. Cytokine therapeutics can be applied to modulate dysregulated immune responses in disorders such as cancer or autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
Adipokines in inflammation and metabolic disease
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011) · Nature Reviews Immunology · doi:10.1038/nri2921 · Cited by 4,625
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Macrophage Cytokines: Involvement in Immunity and Infectious Diseases
Arango Duque, G., & Descoteaux, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00491 · Cited by 2,708
Defining trained immunity and its role in health and disease
Netea, M. G., Domínguez-Andrés, J., Barreiro, L. B., Chavakis, T., Divangahi, M., Fuchs, E., Joosten, L. A. B., van der Meer, J. W. M., Mhlanga, M. M., Mulder, W. J. M., et al. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0285-6 · Cited by 2,690
Self-citationIn search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687
Research works printed but not linked: 171
- Altan-Bonnet, G. & Mukherjee, R. Cytokine-mediated communication: a quantitative appraisal of immune complexity. Nat. Rev. Immunol. 19, 205–217 (2019). · DOI · Paper page
- Stanley, A. C. & Lacy, P. Pathways for cytokine secretion. Physiology 25, 218–229 (2010). · DOI · Paper page
- Leonardi, C. L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665–1674 (2008). · DOI · Paper page
- Saenz, S. A., Taylor, B. C. & Artis, D. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol. Rev. 226, 172–190 (2008). · DOI · Paper page
- Eyerich, S., Eyerich, K., Cavani, A. & Schmidt-Weber, C. IL-17 and IL-22: siblings, not twins. Trends Immunol. 31, 354–361 (2010). · DOI · Paper page
- Gharee-Kermani, M. & Pham, S. Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr. Pharm. Des. 7, 1083–1103 (2001). · DOI · Paper page
- Hughes, C. E. & Nibbs, R. J. B. A guide to chemokines and their receptors. FEBS J. 285, 2944–2971 (2018). · DOI · Paper page
- Roan, F., Obata-Ninomiya, K. & Ziegler, S. F. Epithelial cell-derived cytokines: more than just signaling the alarm. J. Clin. Invest. 129, 1441–1451 (2019). · DOI · Paper page
- Smith, D. E. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin. Exp. Allergy 40, 200–208 (2010). · DOI · Paper page
- Ihle, J. N. Cytokine receptor signalling. Nature 377, 591–594 (1995). · DOI · Paper page
- O’Shea, J. J., Gadina, M. & Siegel, R. M. in Clinical Immunology 5th edn Ch. 9 (eds Rich, R. R. et al.) 127–155.e1 (2019). · DOI
- Arts, R. J. W. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23, 89–100.e5 (2018). · DOI · Paper page
- Guo, L., Junttila, I. S. & Paul, W. E. Cytokine-induced cytokine production by conventional and innate lymphoid cells. Trends Immunol. 33, 598 (2012). · DOI
- Rousset, F., Garcia, E. & Banchereau, J. Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J. Exp. Med. 173, 705–710 (1991). · DOI · Paper page
- Tough, D. F., Borrow, P. & Sprent, J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272, 1947–1950 (1996). · DOI · Paper page
- Ross, M. E. & Caligiuri, M. A. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 89, 910–918 (1997). · DOI
- Lin, J. X. et al. The role of shared receptor motifs and common stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2, 331–339 (1995). · DOI · Paper page
- Berraondo, P. et al. Cytokines in clinical cancer immunotherapy. Br. J. Cancer 120, 6–15 (2019). · DOI · Paper page
- Ozaki, K. & Leonard, W. J. Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. 277, 29355–29358 (2002). · DOI · Paper page
- Yoshimoto, T. et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J. Immunol. 161, 3400–3407 (1998). · DOI · Paper page
- Waldmann, T. A. The shared and contrasting roles of interleukin-2 (IL-2) and IL-15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol. Res. 3, 219 (2015). · DOI · Paper page
- Royall, J. A. et al. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 257, L399–L410 (1989). · DOI · Paper page
- Hafler, D. A. Cytokines and interventional immunology. Nat. Rev. Immunol. 7, 423–423 (2007). · doi:10.1038/nri2101
- Monaco, C., Nanchahal, J., Taylor, P. & Feldmann, M. Anti-TNF therapy: past, present and future. Int. Immunol. 27, 55–62 (2015). · DOI · Paper page
- Ly, K. et al. Anti IL-17 in psoriasis. Expert Rev. Clin. Immunol. 15, 1185–1194 (2019). · DOI
- van de Veerdonk, F. L. et al. A guide to immunotherapy for COVID-19. Nat. Med. 28, 39–50 (2022). · DOI · Paper page
- Herman, A. C., Boone, T. C. & Lu, H. S. in Formulation, Characterization, and Stability of Protein Drugs (eds Pearlman, R. & Wang, Y. J.) 303–328 (Springer, 2002). · doi:10.1007/0-306-47452-2_7
- Rasenack, J. et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]. Pharmacoeconomics 21, 341–349 (2003). · DOI
- Baldo, B. A. Side effects of cytokines approved for therapy. Drug Safety 37, 921–943 (2014). · DOI · Paper page
- Golomb, H. M. et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J. Clin. Oncol. 4, 900–905 (1986). · doi:10.1200/jco.1986.4.6.900
- Cohen, J. IL-12 deaths: explanation and a puzzle. Science 270, 908 (1995). · doi:10.1126/science.270.5238.908.a · Paper page
- Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105–2116 (1999). · DOI · Paper page
- Sanger, F., Nicklen, S. & Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl Acad. Sci. USA 74, 5463–5467 (1977). · DOI · Paper page
- Karas, M. & Hillenkamp, F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal. Chem. 60, 2299–2301 (1988). · DOI · Paper page
- Tanaka, K. et al. Protein and polymer analyses up to mlz 100 000 by laser ionization time-of-flight mass spectrometry. Rapid Commun. Mass. Spectrom. 2, 151–153 (1988). · DOI · Paper page
- Williamson, M. P., Havel, T. F. & Wüthrich, K. Solution conformation of proteinase inhibitor IIA from bull seminal plasma by 1H nuclear magnetic resonance and distance geometry. J. Mol. Biol. 182, 295–315 (1985). · DOI · Paper page
- Woolfson, M. M. The development of structural x-ray crystallography. Phys. Scr. 93, 032501 (2018). · DOI
- Matadeen, R., Hon, W. C., Heath, J. K., Jones, E. Y. & Fuller, S. The dynamics of signal triggering in a gp130-receptor complex. Structure 15, 441–448 (2007). · DOI
- Wang, X., Rickert, M., Garcia, K. C. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 310, 1159–1163 (2005). · DOI · Paper page
- Gaffen, S. L. Signaling domains of the interleukin 2 receptor. Cytokine 14, 63–77 (2001). · DOI · Paper page
- Johnson, K., Granzow, R., Creasey, A. & Ciardelli, T. Ligand binding analyses and functional activity of interleukin-2 receptor ectodomains. Methods 6, 199–205 (1994). · doi:10.1006/meth.1994.1022
- Truneh, A. et al. Temperature-sensitive differential affinity of TRAIL for its receptors: DR5 is the highest affinity receptor. J. Biol. Chem. 275, 23319–23325 (2000). · DOI · Paper page
- Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature 484, 529–533 (2012). The researchers employed directed evolution to engineer an IL-2 ‘superkine’ (MDNA11) with improved antitumour properties and reduced toxicity that is now undergoing a phase I/II clinical trial. · DOI · Paper page
- Lumsden, A. & Wilkinson, D. The promise of gene ablation. Nature 347, 335–336 (1990). · DOI
- Kluger, M. J., Kozak, W., Leon, L. R. & Conn, C. A. The use of knockout mice to understand the role of cytokines in fever. Clin. Exp. Pharmacol. Physiol. 25, 141–144 (1998). · DOI
- Ingman, W. V. & Jones, R. L. Cytokine knockouts in reproduction: the use of gene ablation to dissect roles of cytokines in reproductive biology. Hum. Reprod. Update 14, 179–192 (2008). · DOI
- McCaughtry, T. M. et al. Conditional deletion of cytokine receptor chains reveals that IL-7 and IL-15 specify CD8 cytotoxic lineage fate in the thymus. J. Exp. Med. 209, 2263–2276 (2012). · DOI
- Archambault, L. S., Trzilova, D., Gonia, S., Gale, C. & Wheeler, R. T. Intravital imaging reveals divergent cytokine and cellular immune responses to Candida albicans and Candida parapsilosis. mBio 10, e00266-19 (2019). · DOI
- van de Donk, P. P. et al. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. Eur. J. Nucl. Med. Mol. Imaging 48, 4369–4376 (2021). · DOI
- Zhang, T., Warden, A. R., Li, Y. & Ding, X. Progress and applications of mass cytometry in sketching immune landscapes. Clin. Transl Med. 10, e206 (2020). · DOI
- Iyer, A., Hamers, A. A. J. & Pillai, A. B. CyTOF® for the masses. Front. Immunol. 13, 815828 (2022). · DOI
- Jiang, P. et al. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. Nat. Methods 18, 1181–1191 (2021). · DOI · Paper page
- Hahn, N. et al. The orphan cytokine receptor CRLF3 emerged with the origin of the nervous system and is a neuroprotective erythropoietin receptor in locusts. Front. Mol. Neurosci. 12, 251 (2019). · DOI
- Carter, P. Site-directed mutagenesis. Biochemistry 237, 1–7 (1986). · DOI · Paper page
- Packer, M. S. & Liu, D. R. Methods for the directed evolution of proteins. Nat. Rev. Genet. 16, 379–394 (2015). · DOI · Paper page
- Krieg, C., Létourneau, S., Pantaleo, G. & Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl Acad. Sci. USA 107, 11906–11911 (2010). · DOI · Paper page
- Junttila, I. S. et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat. Chem. Biol. 8, 990–998 (2012). · DOI
- Mueller, T. D., Zhang, J.-L., Sebald, W. & Duschl, A. Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim. Biophys. Acta Mol. Cell Res. 1592, 237–250 (2002). · DOI · Paper page
- Gorby, C. et al. Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses. Sci. Signal. 13, eabc0653 (2020). · DOI
- Zhou, T. et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609–614 (2020). · DOI · Paper page
- Saxton, R. A. et al. The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design. Immunity 54, 660–672.e9 (2021). · DOI
- Saxton, R. A. et al. Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10. Science 371, eabc8433 (2021). · DOI · Paper page
- Mendoza, J. L. et al. Structure of the IFNγ receptor complex guides design of biased agonists. Nature 567, 56–60 (2019). · DOI
- Carmenate, T. et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 190, 6230–6238 (2013). · DOI
- Chen, X. et al. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2. Cell Death Dis. 9, 989 (2018). · doi:10.1038/s41419-018-1047-2
- Shanafelt, A. B. et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat. Biotechnol. 18, 1197–1202 (2000). · DOI
- Peterson, L. B. et al. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. J. Autoimmun. 95, 1–14 (2018). · DOI
- Ghelani, A. et al. Defining the threshold IL-2 signal required for induction of selective Treg cell responses using engineered IL-2 muteins. Front. Immunol. 11, 1106 (2020). · DOI
- Visweswaraiah, J. et al. Generation of PT101, a highly selective IL-2 mutein for treatment of autoimmune diseases. Ann. Rheum. Dis. 80, 13–13 (2021). · doi:10.1136/annrheumdis-2021-eular.2097
- Khoryati, L. et al. An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice. Sci. Immunol. 5, eaba5264 (2020). · DOI
- Molineux, G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 23, 3S–8S (2003). · DOI
- Meyers, F. J., Paradise, C., Scudder, S. A., Goodman, G. & Konrad, M. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2. Clin. Pharmacol. Ther. 49, 307–313 (1991). · DOI
- Mattijssen, V. et al. Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma. Ann. Oncol. 5, 957–960 (1994). · doi:10.1093/oxfordjournals.annonc.a058739
- Emmerich, J. et al. IL-10 directly activates and expands tumor-resident CD8+ T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 72, 3570–3581 (2012). · DOI · Paper page
- Naing, A. et al. PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients. Cancer Cell 34, 775–791.e3 (2018). · DOI · Paper page
- Ptacin, J. L. et al. An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism. Nat. Commun. 12, 4785 (2021). The researchers developed a rationally PEGylated form of IL-2 (THOR-707) that selectively expands and activates effector T cells and NK cells and is undergoing a phase I/II clinical trial. · DOI
- Charych, D. H. et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin. Cancer Res. 22, 680–690 (2016). · DOI · Paper page
- Dixit, N. et al. NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J. Transl Autoimmun. 4, 100103 (2021). · DOI
- Miyazaki, T. et al. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy. J. Immunother. Cancer 9, e002024 (2021). · DOI
- Sellaturay, P., Nasser, S., Islam, S., Gurugama, P. & Ewan, P. W. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin. Exp. Allergy 51, 861–863 (2021). · DOI · Paper page
- Pan, X. & Kortemme, T. Recent advances in de novo protein design: principles, methods, and applications. J. Biol. Chem. 296, 100558 (2021). · DOI · Paper page
- Goldenzweig, A. et al. Automated structure- and sequence-based design of proteins for high bacterial expression and stability. Mol. Cell 63, 337–346 (2016). · DOI · Paper page
- Khersonsky, O. et al. Automated design of efficient and functionally diverse enzyme repertoires. Mol. Cell 72, 178–186.e5 (2018). · DOI · Paper page
- Wang, J., Cao, H., Zhang, J. Z. H. & Qi, Y. Computational protein design with deep learning neural networks. Sci. Rep. 8, 6349 (2018). · DOI · Paper page
- Lin, E., Lin, C. H. & Lane, H. Y. De novo peptide and protein design using generative adversarial networks: an update. J. Chem. Inf. Model. 62, 761–774 (2022). · DOI
- Leman, J. K. et al. Macromolecular modeling and design in Rosetta: recent methods and frameworks. Nat. Methods 17, 665–680 (2020). · DOI · Paper page
- Yen, M. et al. Facile discovery of surrogate cytokine agonists. Cell 185, 1414–1430.e19 (2022). · DOI
- Moraga, I. et al. Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers. eLife 6, 22882 (2017). · DOI
- Emmerich, J. et al. Abstract 1744: STK-012, an α/β selective IL-2 mutein for the activation of the antigen-activated T cells in solid tumor. Cancer Res. 81, 1744–1744 (2021). · doi:10.1158/1538-7445.am2021-1744
- Ren, J. et al. Interleukin-2 superkines by computational design. Proc. Natl Acad. Sci. USA 119, e2117401119 (2022). · DOI
- Harvill, E. T. & Morrison, S. L. An IgG3–IL2 fusion protein activates complement, binds FcγRI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1, 95–105 (1995). · doi:10.1016/1380-2933(95)00009-7
- Peng, L. S., Penichet, M. L. & Morrison, S. L. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. 163, 250–258 (1999). · doi:10.4049/jimmunol.163.1.250
- Halin, C. et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 20, 264–269 (2002). · DOI · Paper page
- Castellani, P. et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59, 612–618 (1994). · DOI · Paper page
- Fallon, J. et al. The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget 5, 1869–1884 (2014). The researchers fused IL-12 to a histone-binding antibody to engineer an immunocytokine target’s exposed DNA found at the site of the tumour. · DOI · Paper page
- Zhang, L. et al. Imaging the alternatively spliced D domain of tenascin C in preclinical models of inflammatory bowel disease. Mol. Imaging Biol. https://doi.org/10.1007/s11307-022-01758-6 (2022). · DOI
- Tzeng, A., Kwan, B. H., Opel, C. F., Navaratna, T. & Wittrup, K. D. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc. Natl Acad. Sci. USA 112, 3320–3325 (2015). · DOI
- Spangler, J. B. et al. Engineering a single-agent cytokine/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy. J. Immunol. 201, 2094–2106 (2018). · DOI
- Huyghe, L. et al. Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies. EMBO Mol. Med. 12, e11223 (2020). · DOI
- Cauwels, A. & Tavernier, J. Tolerizing strategies for the treatment of autoimmune diseases: from ex vivo to in vivo strategies. Front. Immunol. 11, 674 (2020). · DOI
- Hank, J. A. et al. Immunogenicity of the Hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin. Cancer Res. 15, 5923–5930 (2009). · doi:10.1158/1078-0432.ccr-08-2963
- Momin, N. et al. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci. Transl Med. 11, 2614 (2019). The researchers fused pro-inflammatory cytokines to a collagen-binding protein to engineer cytokine fusion proteins with increased tumour retention. · DOI · Paper page
- Agarwal, Y. et al. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat. Biomed. Eng. 6, 129–143 (2022). · DOI
- Mansurov, A. et al. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat. Biomed. Eng. 4, 531–543 (2020). · DOI · Paper page
- Rautio, J., Meanwell, N. A., Di, L. & Hageman, M. J. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Discov. 17, 559–587 (2018). · DOI · Paper page
- López-Otín, C. & Matrisian, L. M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800–808 (2007). · DOI · Paper page
- Hsu, E. J. et al. A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nat. Commun. 12, 2768 (2021). · DOI
- O’Neil, J. et al. Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates. J. Clin. Oncol. 39, 2563–2563 (2021). The researchers developed an IL-2 prodrug that is inactive until the inactivation unit is cleaved by tumour-associated proteases. · doi:10.1200/jco.2021.39.15_suppl.2563
- Mansurov, A. et al. Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nat. Biomed. Eng. 6, 819–829 (2022). · DOI
- Nirschl, C. et al. WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models. J. Immunother. Cancer 9, A747–A747 (2021). · doi:10.1136/jitc-2021-sitc2021.718
- Steiner, P. et al. Conditionally activated IL-12 or IFNα indukineTM molecules inhibit syngeneic lymphoma tumor growth in mice, induce anti-tumor immune responses and are tolerated in non-human primates. Blood 138, 2258–2258 (2021). · doi:10.1182/blood-2021-152758
- Rosen, D. B. et al. TransConTM IL-2 β/γ: a novel long-acting prodrug of receptor-biased IL-2 designed for improved pharmocokinetics and optimal activation of T cells for the treatment of cancer [abstract 4507]. Immunology 80, 4507–4507 (2020).
- Zhang, Y., Li, N., Suh, H. & Irvine, D. J. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat. Commun. 9, 6 (2018). The researchers anchored IL-2 and anti-CD137 on the surface of liposomes to improve tumour accumulation and decrease systemic toxicity. · DOI · Paper page
- Kamaly, N. et al. Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis. ACS Nano 10, 5280–5292 (2016). · DOI · Paper page
- Kawasaki, T. & Kawai, T. Toll-like receptor signaling pathways. Front. Immunol. 5, 461 (2014). · DOI · Paper page
- Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e7 (2021). · DOI · Paper page
- Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer–BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543–555 (2022). · DOI · Paper page
- Liu, J. Q. et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J. Control. Release 345, 306–313 (2022). · DOI · Paper page
- Hotz, C. et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci. Transl Med. 13, eabc7804 (2021). · DOI · Paper page
- Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558–576 (2021). · DOI · Paper page
- Lai, I. et al. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. J. Immunother. Cancer 6, 125 (2018). In this study, a lipid nanoparticle encapsulating mRNA encoding IL-12 was intravenously administered to treat hepatocellular carcinoma. · DOI
- van Leent, M. M. T. et al. Regulating trained immunity with nanomedicine. Nat. Rev. Mater. 7, 465–481 (2022). · DOI
- Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer 124, 1759–1776 (2021). · DOI · Paper page
- Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268–276 (2013). · DOI · Paper page
- Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S. & Brentjens, R. J. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 4, e994446 (2015). · DOI · Paper page
- Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D. & Brentjens, R. J. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. Rep. 7, 10541 (2017). · DOI · Paper page
- Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278–2288 (2015). · DOI · Paper page
- Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372–385 (2019).
- Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99, 16168–16173 (2002). · DOI · Paper page
- Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346–351 (2018). · DOI · Paper page
- Andersen, R. et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin. Cancer Res. 22, 3734–3745 (2016). · DOI · Paper page
- Lee, J. M. et al. Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model. Cancer Gene Ther. 17, 742–750 (2010). · DOI
- Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359, 1037–1042 (2018). The researchers developed an orthogonal IL-2 cytokine–receptor complex that selectively potentiates engineered T cells for engineered cell therapies. · DOI · Paper page
- Zhang, Q. et al. A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci. Transl Med. 13, 6986 (2021). · DOI
- Hirai, T. et al. Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance. J. Clin. Invest. 131, e139991 (2021). · DOI
- Taylor, P. A. et al. L-selectinhi but not the L-selectinlo CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104, 3804–3812 (2004). · DOI · Paper page
- Mo, F. et al. An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature 597, 544–548 (2021). · DOI · Paper page
- Pohl-Guimarães, F. et al. RNA-modified T cells mediate effective delivery of immunomodulatory cytokines to brain tumors. Mol. Ther. 27, 837–849 (2019). · DOI
- Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic Notch receptors. Cell 167, 419–432.e16 (2016). · DOI · Paper page
- Yao, W. et al. Intratumoral injection of dendritic cells overexpressing interleukin-12 inhibits melanoma growth. Oncol. Rep. 42, 370–376 (2019).
- Minkis, K. et al. Type 2 bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res. 68, 9441–9450 (2008). · DOI
- Tatsumi, T. et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity 1. Cancer Res. 63, 6378–6386 (2003).
- Bontkes, H. J. et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther. 14, 366–375 (2007). · DOI
- Naka, T. et al. Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA. Cancer Sci. 99, 407–413 (2008). · DOI
- van den Bergh, J. et al. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget 6, 44123–44133 (2015). · DOI
- Kang, M. et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv. Mater. 33, 2103258 (2021). · DOI · Paper page
- Wang, S. et al. CAR-macrophage: an extensive immune enhancer to fight cancer. eBioMedicine 76, 103873 (2022). · DOI
- Kaczanowska, S. et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. Cell 184, 2033–2052.e21 (2021). · DOI · Paper page
- Nash, A. M. et al. Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. Sci. Adv. 8, 1032 (2022). · DOI
- Mosallaei, M. et al. Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication. Cancer Gene Ther. 27, 854–868 (2020). · DOI
- Razeghian, E. et al. Mesenchymal stem/stromal cells as a vehicle for cytokine delivery: an emerging approach for tumor immunotherapy. Front. Med. 8, 1405 (2021). · DOI
- Adams, G. P. & Weiner, L. M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147–1157 (2005). · DOI · Paper page
- Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996). · DOI · Paper page
- Perrillo, R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 49, S103–S111 (2009). · DOI · Paper page
- Panitch, H. S. Interferons in multiple sclerosis. Drugs 44, 946–962 (1992). · DOI
- Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688–696 (1995). · DOI · Paper page
- Bennett, C. L., Djulbegovic, B., Norris, L. B. & Armitage, J. O. Colony-stimulating factors for febrile neutropenia during cancer therapy. N. Engl. J. Med. 368, 1131–1139 (2013). · DOI · Paper page
- Zhang, P., Sun, F., Liu, S. & Jiang, S. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J. Control. Release 244, 184–193 (2016). · DOI · Paper page
- Mitra, S. et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 42, 826–838 (2015). · DOI · Paper page
- Mould, D. R. & Green, B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24, 23–39 (2010). · DOI · Paper page
- Ghoreschi, K. et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9, 40–46 (2002). · DOI · Paper page
- Tulpule, A. et al. Interleukin-4 in the treatment of AIDS-related Kaposi’s sarcoma. Ann. Oncol. 8, 79–83 (1997). · DOI
- Sportès, C. et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 205, 1701–1714 (2008). · DOI · Paper page
- Buruiana, F. E., Solà, I. & Alonso-Coello, P. Recombinant human interleukin 10 for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2012, CD005109 (2010).
- Colombel, J. F. et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn’s disease. Gut 49, 42–46 (2001). · DOI · Paper page
- Chernoff, A. E. et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J. Immunol. 154, 5492–5499 (1995). · DOI · Paper page
- Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74–82 (2015). · DOI · Paper page
- Petrella, T. M. et al. Final efficacy results of NCIC CTG IND.202: a randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM). J. Clin. Oncol. 31, 9032–9032 (2013). · doi:10.1200/jco.2013.31.15_suppl.9032
- Pina, A. S., Lowe, C. R. & Roque, A. C. A. Challenges and opportunities in the purification of recombinant tagged proteins. Biotechnol. Adv. 32, 366–381 (2014). · DOI · Paper page
- Malyala, P. & Singh, M. Endotoxin limits in formulations for preclinical research. J. Pharm. Sci. 97, 2041–2044 (2008). · DOI · Paper page
- Freitag, R. in Animal Cell Biotechnology Vol. 1104 (ed. Pörtner, R.) 419–458 (Humana, 2014). · DOI
Cited by
Strategies for targeting cytokines in inflammatory bowel disease
Neurath, M. F. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-024-01008-6 · Cited by 398
Integrating Computational Design and Experimental Approaches for Next-Generation Biologics
Son, A., Park, J., Kim, W., Lee, W., Yoon, Y., Ji, J., & Kim, H. (2024) · Biomolecules · doi:10.3390/biom14091073 · Cited by 29
Metadata
- Authors
- Deckers, J., Anbergen, T., Hokke, A. M., de Dreu, A., Schrijver, D. P., de Bruin, K., Toner, Y. C., Beldman, T. J., Spangler, J. B., de Greef, T. F. A., Grisoni, F., van der Meel, R., Joosten, L. A. B., Merkx, M., Netea, M. G., & Mulder, W. J. M.
- Venue
- Nature Reviews Bioengineering
- Published
- 2023-02-16
- Volume
- 1
- Issue
- 4
- Pages
- 286-303
- ISSN
- 2731-6092 (ISSN-L)
- OpenAlex
- W4321112890
- Cited by
- 214
- References
- 46
- FWCI
- 10.29
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-03-27)
- Open access
- bronze
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineering cytokine therapeutics. https://app.cochat.ai/papers/10.1038/s44222-023-00030-y
- The paper
- Deckers, J., Anbergen, T., Hokke, A. M., de Dreu, A., Schrijver, D. P., de Bruin, K., Toner, Y. C., Beldman, T. J., Spangler, J. B., de Greef, T. F. A., Grisoni, F., van der Meel, R., Joosten, L. A. B., Merkx, M., Netea, M. G., & Mulder, W. J. M. (2023). Engineering cytokine therapeutics. Nature Reviews Bioengineering. https://doi.org/10.1038/s44222-023-00030-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.